169 related articles for article (PubMed ID: 7431220)
1. Evaluation of the absorption from some commercial enteric-release theophylline products.
Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the absorption from some commercial sustained-release theophylline products.
Upton RA; Thiercelin JF; Guentert TW; Sansom L; Powell JR; Coates PE; Riegelman S
J Pharmacokinet Biopharm; 1980 Apr; 8(2):131-49. PubMed ID: 7431219
[TBL] [Abstract][Full Text] [Related]
3. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
Osman MA; Patel RB; Irwin DS; Welling PG
Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
[TBL] [Abstract][Full Text] [Related]
4. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
5. The relation of product formulation to absorption of oral theophylline.
Weinberger M; Hendeles L; Bighley L
N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
[TBL] [Abstract][Full Text] [Related]
7. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
8. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet.
Leeds NH; Gal P; Purohit AA; Walter JB
J Clin Pharmacol; 1982 Apr; 22(4):196-200. PubMed ID: 7096605
[TBL] [Abstract][Full Text] [Related]
11. Dissolution studies of some sustained-release theophylline dosage forms.
Simons KJ; Simons FE; Plett KD; Scerbo C
J Pharm Sci; 1984 Jul; 73(7):939-42. PubMed ID: 6470957
[TBL] [Abstract][Full Text] [Related]
12. Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets.
Sansom LN; Milne RW; Cooper D
Eur J Clin Pharmacol; 1979; 16(6):417-21. PubMed ID: 583332
[TBL] [Abstract][Full Text] [Related]
13. Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.
Lagas M; Jonkman JH
Eur J Clin Pharmacol; 1983; 24(6):761-7. PubMed ID: 6884413
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria.
Upton RA; Sansom L; Guentert TW; Powell JR; Thiercelin JF; Shah VP; Coates PE; Riegelman S
J Pharmacokinet Biopharm; 1980 Jun; 8(3):229-42. PubMed ID: 7420268
[TBL] [Abstract][Full Text] [Related]
16. [Preparation and evaluation of press-coated aminophylline tablet using crystalline cellulose and polyethylene glycol in the outer shell for timed-release dosage forms].
Watanabe Y; Mukai B; Kawamura K; Ishikawa T; Namiki M; Utoguchi N; Fujii M
Yakugaku Zasshi; 2002 Feb; 122(2):157-62. PubMed ID: 11857956
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
18. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
Simons KJ; Frith EM; Simons FE
J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
[TBL] [Abstract][Full Text] [Related]
19. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
Hendeles L; Iafrate RP; Weinberger M
Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
[TBL] [Abstract][Full Text] [Related]
20. A multiple-dose study of sustained-release theophylline and aminophylline.
Meyer MC; Straughn AB; Lieberman P
Chest; 1980 Aug; 78(2):300-3. PubMed ID: 7398417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
